Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 4/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MASP2 | O00187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209136 | 0.95 | HDAC1 (0.38) | HDAC1ACHEROCK2PRKG1PRKCE | |
| SCHEMBL7431095 | 0.90 | HDAC1 (0.38) | HDAC1ACHEROCK2PRKG1PRKCE | |
| SCHEMBL5210913 | 0.84 | NPC1 (0.39) | HDAC1ROCK2PRKG1PRKCEPKN2 | |
| SCHEMBL5210889 | 0.84 | NPC1 (0.40) | HDAC1ROCK2PRKG1PRKCEPKN2 | |
| SCHEMBL5214004 | 0.83 | HDAC1 (0.45) | HDAC1BRD4CREBBPGLSNAMPT | |
| SCHEMBL5210074 | 0.83 | RXRB (0.38) | HDAC1ROCK2PRKG1PRKCEPKN2 | |
| SCHEMBL5216930 | 0.82 | RAB9A (0.37) | HDAC1ROCK2PRKG1PRKCEPKN2 | |
| Trifluoroacetic Acid SCHEMBL5216054 | 0.81 | ACHE (0.38) | ACHEF2KDM1A | |
| Trifluoroacetic Acid SCHEMBL4807978 | 0.80 | NPC1 (0.37) | HDAC1ROCK2PRKG1PRKCEPKN2 | |
| SCHEMBL5209066 | 0.78 | CYP2D6 (0.49) | F2GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | HDAC1 1854/4885ACHE 480/4885ROCK2 3158/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | HDAC1 1700/4885ACHE 1165/4885ROCK2 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.